These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18070716)

  • 1. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.
    Facon T; Darre S
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):737-46. PubMed ID: 18070716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline treatment in elderly patients with multiple myeloma.
    Facon T; San Miguel J; Mateos MV; Hulin C
    Semin Hematol; 2009 Apr; 46(2):133-42. PubMed ID: 19389497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Front line treatment of elderly multiple myeloma in the era of novel agents.
    Venon MD; Roccaro AM; Gay J; Moreau AS; Dulery R; Facon T; Ghobrial IM; Leleu X
    Biologics; 2009; 3():99-109. PubMed ID: 19707399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of newly diagnosed myeloma.
    Rajkumar SV; Palumbo A
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
    Kapoor P; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Mikhael JR; Roy V; Kyle RA; Greipp PR; Kumar S; Mandrekar SJ
    Leukemia; 2011 Apr; 25(4):689-96. PubMed ID: 21233832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
    Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
    N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
    Hernández JM; García-Sanz R; Golvano E; Bladé J; Fernandez-Calvo J; Trujillo J; Soler JA; Gardella S; Carbonell F; Mateo G; San Miguel JF
    Br J Haematol; 2004 Oct; 127(2):159-64. PubMed ID: 15461621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
    Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS
    Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on recent developments for patients with newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
    Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma in the elderly: when to treat, when to go to transplant.
    Harousseau JL
    Oncology (Williston Park); 2010 Oct; 24(11):992-8. PubMed ID: 21155446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.